A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: Pharmacodynamic and microbiological aspects

Revista Espanola de Quimioterapia

Volumn 23, Issue 2, 2010, Pages 103-108

  Candel, F J ^a   Calvo, N ^a   Head, J ^a   Sanchez A ^a   Matesanz, M ^a   Culebras, E ^a   Barrientos, A ^a   Picazo, J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Bacteremia; Colistin; Continuousinfusion of meropenem; Manganese; Mueller Hinton agar; Multirresistant Acinetobacter baumannii; Tigecycline

Indexed keywords

AGAR; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEMASE; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; FLUDROCORTISONE; FOSFOMYCIN; IMIPENEM; MANGANESE; MEROPENEM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXACILLINASE; PREDNISONE; TACROLIMUS; TIGECYCLINE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; AGED; ARTICLE; BACTEREMIA; BLOOD CULTURE; CASE REPORT; CREATININE CLEARANCE; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; KIDNEY GRAFT; LABORATORY TEST; MULTIDRUG RESISTANCE; PNEUMONIA; SPAIN; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIENAMYCINS;

EID: 77956470235     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Shafer JJ; Goff DA; Stevenson KB; Mangino JE. Early experience with tigecycline for ventilador-associated pneumonia and bacteriemia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007; 27: 980-987.
2. Kuo LC; Lai CC; Liao CH; Hsu CK; Chang YL; Chang CY; Hsueh PR. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007; 13: 196-198.
3. Thamlikitkul V, Tiengrim S. Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp. J Antimicrob Chemother. 2008; 62: 847-848.
4. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST) Group. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis. 2005; 52: 173-179.
5. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis. 2005; 52: 187-193.
6. Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol. 2007; 45: 227-230.
7. Coelho J., Woodford N, Afzal-Shah M and Livermore D. Occurrence of OXA-58-like carbapenemases in Acinetobacter spp collected over 10 years in three continents. Antimicrob. Agents Chemother. 2006. 50:756-758.
8. Ruiz M, Martí S, Fernandez-Cuenca F., Pascual A and Vila J. High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated Acinetobacter baumannii clinical isolates in Spain. Clin Microbiol Infect. 2007; 13: 1192-1198.
9. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, Husain S, Kwak EJ, Bhat SV, Paterson DL. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007; 59: 128-131.
10. Li, J; Nation RL. Old polymyxins are back: is resistance close? Clin. Infect. Dis 2006. 43:663-664.
11. Kroeger LA, Hovde LB, Mitropoulos IF, Schafer J, Rotschafer JC. Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2007; 51: 3431-3433.
12. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2007; 51: 3413-3415
13. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, Mussap M, Artioli S, Ansaldi F, Durando P, Orengo G, Bobbio Pallavicini F, Viscoli C. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2008; 61: 417-420.
14. Cobo J, Morosini MI, Pintado V, Tato M, Samaranch N, Baquero F, Cantón R. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamase-producing Klebsiella pneumoniae epidemic clone Diagn Microbiol Infect Dis 2008; 60: 319-322
15. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Borraz C, Gudiol F. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother. 2004; 54: 1085-1091.